# A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

> **NCT03345082** · PHASE2 · COMPLETED · sponsor: **Opthea Limited** · enrollment: 366 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** OPT-302
- **BIOLOGICAL:** ranibizumab
- **OTHER:** sham intravitreal injection

## Key facts

- **NCT ID:** NCT03345082
- **Lead sponsor:** Opthea Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-05-14
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345082, "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03345082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*